A Nigerian doctor, Dr. Onyema Ogbuagbu, is at the centre of the
A few days after,
The announcement by
Ogbuagbu, however, said he had been involved in the trials of the vaccines by
An Associate Professor of Medicine and infectious disease specialist at
A 2003 graduate of medicine from the
He was of the belief that if a lot of people received the vaccine and were protected against the virus, it would go a long way in containing its spread, which has been ravaging the world since the outbreak of the virus in
But Ogbuagbu has said preparations were being made already to surmount those challenges.
Ogbuagbu is in the clinician-educator track and Director of the HIV Clinical Trials programme of the Yale AIDS Programme, Section of Infectious
His profile obtained from the website of
He is one of the twin sons of Prof. Chibuzo Ogbuagbu (former VC of ABSU and Abia SSG), whose parents had in
The Ogbuagbus were reported to have returned to
Ogbuagbu's responsibilities at Yale include educating and training medical students, residents and infectious diseases fellows in various capacities in inpatient and outpatient settings; and through structured course work and other teaching sessions.
As a faculty of the HIV training track of the Yale-Internal Medicine primary care programme and for over six years as a faculty of the Human Resources for Health program in
In
In addition, Ogbuagbu has facilitated meaningful educational and research collaborations between faculty and trainees across institutions.
As the programme director of
Overall, his expertise and collective experiences to date had seen him to design and run successful projects around capacity building in low-resource settings, including developing and implementing innovative and robust medical training and research programmes for faculty, fellows, residents and students.
For five years running, he has been the director of the Yale AIDS Programme, HIV clinical trials programme, and a principal investigator on numerous pharmacokinetic, phase 2 and 3 safety and efficacy trials of novel antiviral compounds (HIV).
More recently, given the alarming rate of new infections among men who have sex with men (MSM), he had focused on HIV prevention trials including being a co-principal investigator on a Yale CIRA funded project, which has supported the formation of a cohort of men, who have sex with men and are at high risk for HIV and are engaged in HIV PrEP services in order to study the impact of substance use on retention in care and adherence to PrEP.
Ogbuagbu is also a lead investigator on the international DISCOVER trial evaluating TAF/
Copyright This Day. Distributed by AllAfrica Global Media (allAfrica.com)., source